Sutro Biopharma Inc Granted Fast Track Designation for STRO-002 by the US FDA
Sutro Biopharma Inc (STRO) announced that the U.S. FDA granted Fast Track designation for its STRO-002 – a folate receptor alpha (FolRα)-targeting antibody-drug conjugate (ADC), for the treatment of patients with platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer who have received one to three prior lines of systemic therapy.
From the CMO & CEO of Sutro Biopharma Inc
Dr. Arturo Molina, Chief Medical Officer of Sutro Biopharma Inc expressed the firm’s pleasure with the FDA’s decision, as it opens the door to more frequent interactions with the agency.
Dr. Molina said, “We continue to be enthused by the potential of the STRO-002 program, which has shown encouraging preliminary activity and tolerability in our Phase 1 dose-escalation study in ovarian cancer, and plan to continue to work with the FDA to potentially accelerate our clinical and regulatory efforts.”